linjc16/ctgov huggingface dataset:
Influence of Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Gonarthrosis

Study Overview
=================
Brief Summary
-----------------
40 patients with osteoarthritis of the knee will be randomly assigned to conventional physiotherapy on the one and whole body vibration exercises on the other hand. The duration of the training will be 6 weeks, three times a week. The outcome will be measured by WOMAC and SF-12 scores relating to pain and quality of life. The second outcome criteria will be a motion analysis and balance testing before and after the training. The follow-up is 26 weeks.

Official Title
-----------------
Influence of Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Gonarthrosis

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Behavioral: Conventional physiotherapy
* Behavioral: Whole body vibration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30-80 years old WOMAC 30-70 mm (VAS) Gonarthrosis (Kellgren/Lawrence) II-III Exclusion Criteria: WOMAC >70 mm (VAS) Endoprosthesis in lower extremity BMI >40 kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Whole body vibration<br> | Behavioral: Whole body vibration<br>* 3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.<br>* Other names: Galileo Whole body vibration;|
| Conventional physiotherapy<br> | Behavioral: Conventional physiotherapy<br>* 3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.<br>* Other names: Galileo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Reduction |  | 6 weeks after inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Motion analysis |  | 6 weeks after inclusion | 
| Pain reduction |  | 12 weeks after inclusion | 
| Pain reduction |  | 26 weeks after inclusion | 
| Motion analysis |  | 12 weeks after inclusion | 
| Motion analysis |  | 26 weeks after inclusion | 
| Quality of life |  | 6 weeks after inclusion | 
| Quality of life |  | 12 weeks after inclusion | 
| Quality of life |  | 26 weeks after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Galileo, Whole body vibration, Osteoarthritis, Knee, Physiotherapy
Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis

Study Overview
=================
Brief Summary
-----------------
The costs to a rural emergency medical services (EMS) system of a change from a traditional cyanide antidote kit to a kit containing hydroxocobalamin alone are currently unknown. The purpose of this study is to use current EMS data to calculate the costs to a rural EMS system associated with the adoption of a hydroxocobalamin protocol for the treatment of suspected cyanide exposure.

Official Title
-----------------
Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis

Conditions
-----------------
Cyanide Poisoning

Intervention / Treatment
-----------------
* Drug: Cyanide antidote administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Included in Maine EMS database House Fire Victim Poisoning Exclusion Criteria: No potential cyanide exposure Incomplete data available
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EMS cyanide exposure patients<br> | Drug: Cyanide antidote administration<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacoeconomics, Cost effectiveness, Cyanide, Fire, Emergency Medical Services, Smoke Inhalation
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Study Overview
=================
Brief Summary
-----------------
To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.

Detailed Description
-----------------
The nusinersen expanded access program (EAP) is available at approved treatment centers in select territories. A doctor must decide whether nusinersen treatment is appropriate for each patient, based on the patient's medical history and program eligibility criteria. A full list of participating treatment centers is provided in the 'Contacts and Locations' section of this listing, and is regularly updated. Following local approval and official reimbursement of nusinersen in each territory, the EAP will close and patients will transfer to commercially available drug.

Official Title
-----------------
Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)

Conditions
-----------------
Infantile-onset Spinal Muscular Atrophy

Intervention / Treatment
-----------------
* Drug: Nusinersen


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygote. Onset of clinical signs and symptoms at ≤ 6 months (180 days) of age, consistent with infantile onset, Type I SMA Patient whose care in the opinion of the treating physician meets, and is expected to continue to meet, the guidelines set out in the 2007 Consensus Statement for Standard of Care in SMA Key Exclusion Criteria: Patient is qualified to participate in an ongoing clinical trial with nusinersen Participation in a prior nusinersen study Previous exposure to nusinersen History of brain or spinal cord disease that would interfere with the LP procedures or CSF circulation Presence of implanted shunt for the drainage of CSF or implanted CNS catheter Previous or current participation in a clinical trial with an investigational gene therapy for SMA Participation in a study with an investigational therapy for SMA within 6 months or five half-lives of the investigational drug, whichever is the longer, prior to the first dose of nusinersen. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nusinersen|Administered by intrathecal injection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal Muscular Atrophy, SMA, SMN, SMNRx, ISIS-SMNRx, ISIS-SMN Rx, ISIS 396443, ISIS-396443, ENDEAR, IONIS-SMNRx, IONIS-SMN Rx, EMBRACE, NURTURE, IONIS, BIOGEN, SHINE, Nusinersen
Outcomes of Odontoid Fracture in Skeletally Mature Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate and assess the short-term outcomes of odontoid fracture cases admitted to trauma unit of Assiut university hospital.

Detailed Description
-----------------
patients with completed records, CTs, and Plain radiographs. Sufficient clinical records with documented NDI, The patient will be evaluated in 2 weeks, 6 weeks , and 3 , 6 months post operative .

Official Title
-----------------
Outcomes of Odontoid Fracture in Skeletally Mature Patients in Assuit University Hospital

Conditions
-----------------
Spine Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all skeletally patients with odontoid fractures admitted to Assiut University Hospital - Department of Orthopedics and Trauma between October 2021 and October 2022 Exclusion Criteria: patients who are not available for 6 months follow-up and those with insufficient documentation or records

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the short term outcomes of Odontoid fracture in skeletally mature patients | To use the NDI as assessment tool of outcome | 6 months |
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with chronic hepatitis C infections. IFN-g 1b is not currently approved for the treatment of liver fibrosis.

Detailed Description
-----------------
This study will evaluate the safety and tolerability of IFN-g 1b in patients with advanced liver fibrosis and cirrhosis due to hepatitis C. This study will also evaluate whether IFN-g 1b is effective in reducing the amount of fibrosis in the liver.

Official Title
-----------------
A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.

Conditions
-----------------
Liver Fibrosis, Cirrhosis

Intervention / Treatment
-----------------
* Drug: interferon gamma-1b


Participation Criteria
=================
Eligibility Criteria
-----------------
Men or women 18 to 75 years Chronic hepatitis C infection based on a history of positive anti-HCV antibody and/or HCV RNA History of prior treatment with interferon-a-based therapies or an assessment by the investigator that the patient would not benefit from interferon-a-based therapy or that treatment with interferon-a is contraindicated Stage 4, 5 or 6 liver fibrosis according to the Ishak scoring system. Cannot have presence of clinically evident ascites requiring active diuretic therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal bleeding within the last 2 years (diuretic therapy of stable mild-to-moderate peripheral edema is permitted) Must meet minimum blood chemistry requirements Cannot have unstable or uncontrolled thyroid disease Cannot have a variety of other diseases (listed in protocol Other conditions for enrollment exist which would be discussed with a Clinician upon screening for the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: interferon gamma-1b|100 or 200 mcg, SQ, 3x per week|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ishak fibrosis score |  | 52 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver cirrhosis, hepatitis C, liver fibrosis
Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft

Study Overview
=================
Brief Summary
-----------------
N-acetylcysteine may prevent acute kidney injury in high risk patients undergoing off-pump coronary artery bypass graft.

Official Title
-----------------
Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft

Conditions
-----------------
Postoperative Acute Kidney Injury After Off-pump Coronary Artery Bypass Graft

Intervention / Treatment
-----------------
* Drug: N-acetylcysteine
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing off-pump coronary artery bypass surgery and meets more than one of the following criteria; preoperative serum creatinine > 1.4 mg/dl Age > 70 years Diabetes mellitus left ventricular ejection fraction < 35 % or congestive heart failure (NYHA III or IV) emergency surgery or re-operation Exclusion Criteria: preoperative acute renal failure, patients on dialysis, use of N-acetylcystein within 5 days of surgery, history of hypersensitivity to N-acetylcystein

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NAC group<br>N-acetylcysteine | Drug: N-acetylcysteine<br>* N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs<br>|
| Placebo Comparator: Placebo group<br>Saline | Drug: Saline<br>* Equal volume of normal saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of acute kidney injury |  | within 5 days after surgery |
Master Allergen Child Nutrition. Reintroduction of Small Doses

Study Overview
=================
Brief Summary
-----------------
Reintroduction of small doses of food in allergic children to lightening the elimination diet.

Detailed Description
-----------------
In four groups of allergic children (peanuts, wheat , milk and egg), a reintroduction of 4 small increasing doses of allergen is carried out progressively double-blind placebo- cons , randomized, during a hospitalization. The procedure for reintroduction of small doses (MPD) is stopped at the appearance of intolerance (in taking a dose of allergen or placebo) defined by the onset of allergic symptoms or objective severe abdominal pain within 45 minutes of taking.

Official Title
-----------------
Reintroduction of Small Doses of Food in Allergic Children to Lightening the Elimination Diet.

Conditions
-----------------
Food Allergies

Intervention / Treatment
-----------------
* Other: allegic food
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Allergic children 1 and 16 years for peanut, egg and wheat. So, for milk between 9 months and 16 years. Accurate diagnostic Allergic react rapidly and acute Exclusion Criteria: severe disease

Ages Eligible for Study
-----------------
Minimum Age: 9 Months
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: allergic food<br>Reintroduction procedure for small doses : Administration of the first dose the first dose must be allergic food or placebo Clinical monitoring for 45 minutes Administration of the second dose | Other: allegic food<br>* Reintroduction procedure for small doses : Administration of the first dose Clinical monitoring for 45 minutes Administration of the second dose<br>Other: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerance for each ingested dose is assessed by a clinical score | Tolerance is defined by the absence of allergy symptoms within 45 minutes of ingestion of the allergen dose in the absence of intolerance to previous placebo | 45 minutes |
Heart Rate Variability (HRV) in Pituitary Adenoma

Study Overview
=================
Brief Summary
-----------------
Several studies have been reported that heart rate is known to be associated with prognosis in chronic diseases and acute diseases. For example, a decrease in heart rate following myocardial infarction may lead to a higher mortality rate. It is also known to predict heart failure, diabetic neuropathy, and even depression. The combined pituitary function test artificially induces hypoglycemia to observe the secretion of pituitary hormone. The degree of change in heart rate during hypoglycemia can predict the adequacy of the test, and heart rate can be changed according to the characteristic of the tumor. Also, the prognosis can be predicted based on this. In our study, we used a licensed device approved by KFDA (Korea Food and Drug Administration) to measure heart rate variability in patients with pituitary adenoma.

Official Title
-----------------
A Study to Observe the Change of the Biological Signal (Heart Rate) During the Combined Pituitary Stimulation Test

Conditions
-----------------
Pituitary Adenoma

Intervention / Treatment
-----------------
* Device: T-REX TRI00A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 19 year old Those with Normal blood pressure range: 90mmHg <systolic <140mmHg, 60mmHg <diastolic <100mmHg Voluntary participants who visited Seoul St. Mary's Hospital Exclusion Criteria: Those who have been diagnosed with sleep disorders, diabetes, arrhythmia, psychiatric disorder, physical or mental breakdown, drug addicts Diabetes, hypertension, cardiovascular disease diagnosed by taking a drug related to the disease Pregnant or lactating women Those who drank within 12 hours before participating in the trial Those who are deemed inappropriate by clinical trial researchers

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Case Evaluation by T-REX TRI00A<br>Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A | Device: T-REX TRI00A<br>* Case management consists of confirmation of hospital visit date, checking the adverse effect<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Heart rate variability according to the types of pituitary adenoma |  | 5 month of initial recruit |
Pre and Post Muscular Fatigue - DROP-JUMP TEST

Study Overview
=================
Brief Summary
-----------------
Many studies have related the presence of dynamic valgus with several musculoskeletal injuries of the hip, knee and ankle. The weakness of the hip abductors is cited as one of the factors linked to this poor dynamic alignment of the lower limb, however, motor control can also be one of the factors responsible for the poor alignment of the lower limbs.

Official Title
-----------------
Assessment Protocol on Lower Limbs Aligment Pre and Post Muscular Fatigue During DROP-JUMP TEST

Conditions
-----------------
Motor Control

Intervention / Treatment
-----------------
* Other: drop-jump test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged between 18 and 29 years body mass index between 18.5 and 24.99 sedentary irregularly active no pain no injuries (hip, knee, foot, ankle or lumbar spine) no neurological sequelae Exclusion Criteria: pain during the test

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 29 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: pre and post fatigue assessment<br>assessment pre and post fatigue protocol | Other: drop-jump test<br>* The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lower limb motor control | pre fatigue - DROP-JUMP test | assessment pre fatigue | 
| lower limb motor control | post fatigue - DROP-JUMP test | assessment pos fatigue up to 01 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rehabilitation, lower limb-muscle, alignment, sequence